Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit - PubMed
5 hours ago
- #Exercise Tolerance
- #Sotatercept
- #PAH
- Sotatercept improves exercise tolerance in patients with pulmonary arterial hypertension (PAH).
- The study evaluated the effects of 24-week sotatercept treatment on central and peripheral determinants of aerobic capacity, hemodynamic status, cardiovascular function, and oxygen transport.
- Sotatercept significantly improved peak exercise mean pulmonary artery/cardiac output (PA/CO) ratio, reduced pulmonary vascular resistance, mean PA pressure, and right ventricular (RV) work.
- It enhanced RV-PA coupling across rest and exercise, reduced systemic congestion, and increased resting hemoglobin levels.
- Despite a decrease in resting cardiac output (CO), CO reserve with exercise was enhanced, leading to improved aerobic capacity.
- Sotatercept also improved single-leg exercise performance, convective oxygen delivery, and peripheral oxygen uptake in skeletal muscle.
- The benefits of sotatercept include increased hemoglobin, enhanced RV-PA coupling, CO reserve, and improved skeletal muscle oxygen use.